Beksac, MeralSeval, Guldane CengizPaydas, SemraTuglular, Tulin FiratliArslan, OnderGoker, HakanKaynar, LeylagulAltuntas, FevziAtalay, FigenTeke, Havva UskudarBolaman, Ali ZahitPehlivan, MustafaSonmez, MehmetDemir, Ahmet MuzafferTopcuoglu, PervinYilmaz, MehmetKabukcu, Sibel HaciogluAlbayrak, MuratYurttas, Nurgul OzerSalihoglu, AyseCakar, Merih KizilGurman, Gunhan2020-10-232020-10-2320192152-2650http://hdl.handle.net/11727/4957enginfo:eu-repo/semantics/closedAccesselotuzumabimmunomodulatory drugsMultiple myelomaElotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable >= Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From TurkeyconferenceObject1910E242E243000491229800399